Novo Nordisk (NVO) Stock Surges 6% as FDA Takes Aim at Compounding Rivals

TLDR

• Novo Nordisk stock climbed over 6% after the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks compounding list
• The FDA says there is no clinical need for outsourcing facilities to compound these drugs
• A public comment period runs until June 29, 2026, before a final decision is made
• NVO hit its highest level in over two months, topping the Copenhagen stock exchange on Thursday
• The stock is still down more than 16% year-to-date despite Thursday’s surge

Novo Nordisk stock jumped more than 6% on Thursday after the FDA proposed restricting the compounding of weight-loss drugs, a move that would directly benefit the Danish drugmaker.

Novo Nordisk A/S, NVO

The FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list. The agency said there is no clinical need for outsourcing facilities to compound these medications.

The stock reached its highest point in more than two months on Thursday and was the top performer on the Copenhagen stock exchange.

NVO was trading at around $42.38 at the time of writing, well above its 20-day moving average of $39.03 and its 50-day moving average of $38.87.

Despite Thursday’s move, the stock remains below its 200-day moving average of $50.32 and is still down more than 16% year-to-date.

The FDA has opened a public comment period running until June 29, 2026, before any final ruling is made on the proposal.

What’s Weighing on Novo Nordisk

Novo Nordisk has faced its share of headwinds recently. Health Canada approved the first generic version of Ozempic in Canada, opening the door to new competition in one of its core markets.

In response, the company launched a share buyback program. It has repurchased around 13.4 million B-shares for 3.44 billion Danish kroner since February 2026, as part of a 15 billion kroner, 12-month program.

On the pipeline side, the company has started a Phase 3 trial for a knee osteoarthritis treatment and received FDA fast-track designation for a heart drug.

Q1 2026 earnings are scheduled for May 6.

What the Technicals Say

Short-term momentum is positive. The MACD is on a buy signal and the RSI sits at 54.73, which is moderately bullish.

However, the ADX reading of 17.26 suggests the trend lacks real conviction. The Stochastic RSI is flashing a sell signal, pointing to overbought conditions.

Anton Kharitonov of Traders Union flagged the fragile technical setup, saying weak momentum indicators and overbought readings suggest buyers could lose steam quickly. He pointed to the generic Ozempic risk in Canada as an added concern.

Viktoras Karapetjanc, also of Traders Union, takes a more constructive view. He sees the buyback program and active clinical pipeline as supports for long-term value, describing the current pullback as a potential launchpad.

Market strategist Jainam Mehta sees a tactical range between $40.78 and $43.23 as the key battleground. He said a decisive break above or below those levels would be needed to change the near-term risk picture.

The stock opened Thursday with an upside gap of around $0.37 and gained $1.94, or 4.80%, intraday. Intraday volatility stood at 2.47%.

The post Novo Nordisk (NVO) Stock Surges 6% as FDA Takes Aim at Compounding Rivals appeared first on CoinCentral.